SEC Form SC 13G/A filed

2/16/21 12:23:51 PM ET

Medical/Dental Instruments

Health Care

Get the next $DXCM alert in real time by email

SC 13G/A 1 dxcm13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) DEXCOM INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 252131107 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 564,874 6. Shared Voting Power* 0 7. Sole Dispositive Power* 2,139,304 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,139,304 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 2.2% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: DEXCOM INC Item 1(b) Address of Issuer's Principal Executive Offices: 6340 SEQUENCE DRIVE, SAN DIEGO, CALIFORNIA 92121 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 252131107 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020

Get the next $DXCM alert in real time by email

Recent Analyst Ratings for

$DXCM

Date	Price Target	Rating	Analyst
1/12/2026	$71.00	Equal Weight → Underweight	Barclays
12/2/2025	$75.00	Equal-Weight → Overweight	Morgan Stanley
11/25/2025	$68.00	In-line	Evercore ISI
10/21/2025	$85.00	Buy	Stifel
9/8/2025		Outperform → Perform	Oppenheimer
8/21/2025	$100.00	Buy	Argus
6/16/2025	$102.00	Buy	Truist
5/30/2025	$104.00	Buy	Goldman

More analyst ratings

SEC Form SC 13G/A filed

2/16/21 12:23:51 PM ET

$DXCM

Medical/Dental Instruments

Health Care

Get the next $DXCM alert in real time by email

Recent Analyst Ratings for

$DXCM

Date	Price Target	Rating	Analyst
1/12/2026	$71.00	Equal Weight → Underweight	Barclays
12/2/2025	$75.00	Equal-Weight → Overweight	Morgan Stanley
11/25/2025	$68.00	In-line	Evercore ISI
10/21/2025	$85.00	Buy	Stifel
9/8/2025		Outperform → Perform	Oppenheimer
8/21/2025	$100.00	Buy	Argus
6/16/2025	$102.00	Buy	Truist
5/30/2025	$104.00	Buy	Goldman

More analyst ratings

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DXCM

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$DXCM

$DXCM
Analyst Ratings

Dexcom downgraded by Barclays with a new price target

Dexcom upgraded by Morgan Stanley with a new price target

Evercore ISI initiated coverage on Dexcom with a new price target

$DXCM
Press Releases

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

Dexcom Appoints Rick Osterloh to Board of Directors

Dexcom Announces Upcoming Conference Presentation

$DXCM
SEC Filings

DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by DexCom Inc.

$DXCM
Insider Trading

SEC Form 4 filed by Brown Michael Jon

EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)

Executive Chair Sayer Kevin R was granted 32,749 shares and covered exercise/tax liability with 32,498 shares, increasing direct ownership by 0.06% to 409,241 units (SEC Form 4)

$DXCM
Insider Purchases

President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

$DXCM
Leadership Updates

Dexcom Appoints Rick Osterloh to Board of Directors

Dexcom Appoints Euan Ashley to Board of Directors

Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

$DXCM
Financials

Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

$DXCM
Large Ownership Changes